CLINICAL APPLICATION OF GLUCAROLACTONE TO BLADDER TUMOR
II Effect of SLA on Recurrence of Bladder Tumor
1970 Volume 61 Issue 10 Pages 995-1003
Details
1970 Volume 61 Issue 10 Pages 995-1003
On the basis of Boyland's hypothesis, 2, 5-di-o-acetyl-D-glucaro-(1→4) (6→3)-dilactone (SLA) which has been found to possess a potent inhibitory action on β-glucuronidase activity in vivo was given orally to the post-operative patients with bladder tumor.
SLA was administered to 122 patients while the control group was composed of 92 patients. All the patients were histologically transitional cell type.
One-year follow-up was made with 116 patients in the SLA-group and with 56 patients in the control, and two-years follow-up was made with 78 patients in the former and with 31 patients in the latter.
In the one-year follow-up the recurrence rate was found to be 43% in the control and 24% in the SLA-group, while, in the two-years follow-up, it was 64.5% in the former and 27% in the latter respectively.
On the other hand, in the patients suffering from frequent recurrences the effect of SLA was found to be marked only after long-term administration, suggesting that SLA might suppress the carcinogenic activity of urinary substances possibly originated from tryptophan.
